Despite admonitions that physicians should discuss current information on tamoxifen with their patients, the preponderance of scientific primary and secondary reports and commentaries focus on relative risk information. While current trial results do not answer several important questions and while our individual risk assessment tools are less than ideal, we can lay out absolute risk and benefit data.
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Phillips et al.
(1) have helped us all by portraying the impact of breast cancer in a Canadian population. Their life table numbers emphasize that, in a general western population of 1000, the numbers of deaths from breast cancer are small. For example, among women aged 50-54 years and women aged 60-64 years, three deaths might occur in each age group. These numbers emphasize the importance of focusing on women at substantially greater than average risk for this disease.
While there is reluctance to lay out absolute numbers of excess or prevented events associated with tamoxifen therapy [p. 1383 in (2)], healthy women considering this issue request such information. Using the actual average annual rates in the P-1 study report (2) and multiplying these rates by 5 (excepting the vasomotor and gynecologic symptom numbers), the numbers in Table 1 result. It is notable that some event numbers may in fact represent chance occurrences. The excess levels of vasomotor and gynecologic symptoms with tamoxifen are consistent with other data; e.g., in a carefully studied population of postmenopausal women, we found that, after 6 months and 12 months, respectively, an excess of 23% and 27% of tamoxifen recipients reported substantial overall toxicity (3). Such numbers would suggest dropout rates higher than those that actually occurred in the P-1 study.
What this portrayal of absolute events shows is that, in high-risk cohorts under and 50 years of age or more, the numbers of prevented breast cancers over a 5-year period are small; the number of prevented events in women under 50 years of age markedly exceeds the number of unfavorable events (ignoring symptoms); the number of prevented events in women aged 50 years or more is marginally fewer than the number of unfavorable events (without or with the excess uterine cancer numbers); and 15%-25% (depending on how one looks at the data on symptoms) of all treated women will have what they view as substantial toxicity. With breast cancer prevention, preclinical hormone receptor-positive lesions are treated; the prognosis is excellent for women with clinically diagnosed, small hormone receptor-positive cancers (4) . While, in the P-1 study, no endometrial cancer deaths occurred, in the meta-analysis of adjuvant therapy with tamoxifen (4), an excess of endometrial cancer mortality was found.
Until further follow-up data from the P-1 study or from other studies become available, these absolute numbers tell us roughly what we know.
RICHARD R. LOVE

RESPONSE
The risk/benefit assessment provided by Dr. Love is inappropriate. First, the population selected (the women in the Breast Cancer Prevention Trial) represents a mixture of women who comprise a broad range of 5-year breast cancer risk levels and ages. Because the risk/ benefit ratio is a direct function of breast The concept of severity of the condition must be considered in an appropriate risk/benefit assessment. The complexities of developing methodology for performing risk/benefit assessments for tamoxifen treatment are substantial. The Chantilly Workshop Working Group spent more than 9 months developing statistically sound algorithms to quantify risk/benefit for any subset of the population. The special article describing this work appears in this issue of the Journal (1). Sound conclusions regarding who would or would not be likely to benefit from treatment can be drawn from this type of assessment.
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